Largest GWAS (N=1,126,563) of Alzheimer's Disease Implicates Microglia and Immune Cells
Douglas P. WightmaniD, Iris E. JanseniD, Jeanne E. SavageiD, Alexey A. ShadriniD, Shahram BahramiiD, Arvid RongveiD, Sigrid BørteiD, Bendik Slagsvold WinsvoldiD, Ole Kristian DrangeiD, Amy E. MartinseniD, Anne Heidi SkogholtiD, Cristen J. WilleriD, Geir BråtheniD, Ingunn BosnesiD, Jonas Bille NielseniD, Lars G. FritscheiD, Laurent F. ThomasiD, Linda Margareth PederseniD, Maiken Elvestad GabrielseniD, Marianne Bakke JohnseniD, Tore Wergeland MeisingsetiD, Wei ZhouiD, Petroula ProitsiiD, Angela HodgesiD, Richard DobsoniD, , Daniëlle PosthumaiD
Abstract
Late-onset Alzheimers disease is a prevalent age-related polygenic disease that accounts for 50-70% of dementia cases1. Late-onset Alzheimers disease is caused by a combination of many genetic variants with small effect sizes and environmental influences. Currently, only a fraction of the genetic variants underlying Alzheimers disease have been identified2,3. Here we show that increased sample sizes allowed for identification of seven novel genetic loci contributing to Alzheimers disease. We highlighted eight potentially causal genes where gene expression changes are likely to explain the association. Human microglia were found as the only cell type where the gene expression pattern was significantly associated with the Alzheimers disease association signal. Gene set analysis identified four independent pathways for associated variants to influence disease pathology. Our results support the importance of microglia, amyloid and tau aggregation, and immune response in Alzheimers disease. We anticipate that through collaboration the results from this study can be included in larger meta-analyses of Alzheimers disease to identify further genetic variants which contribute to Alzheimers pathology. Furthermore, the increased understanding of the mechanisms that mediate the effect of genetic variants on disease progression will help identify potential pathways and gene-sets as targets for drug development.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 42
- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Meta-analysis of genetic association with diagnosed Alzheimer’s disease identifies novel risk loci and implicates Abeta, Tau, immunity and lipid processing
B K Kunkle, Benjamin Grenier‐Boley, … Clive Holmes·bioRxiv·Apr 5, 2018
- Integration of Alzheimer’s disease genetics and myeloid genomics reveals novel disease risk mechanisms
Gloriia Novikova, Edoardo M. Marcora, … Alison Goate·Alzheimer s & DementiaPeer-reviewed·Dec 1, 2020
- Genetic variability in response to Aβ deposition influences Alzheimer’s risk
Dervis A. M. Salih, Sevinç Bayram, … Valentina Escott‐Price·bioRxiv·Oct 8, 2018
- Multi-Omics Analysis for Identifying Cell-Type-Specific Druggable Targets in Alzheimer's Disease
Shiwei Liu, Minyoung Cho, … Kwangsik T. Nho·medRxiv·Jan 8, 2025
- A multiple-causal-gene-cluster model underlying GWAS signals of Alzheimer's disease
Min Xu, Qianjin Liu, … Yong‐Gang Yao·bioRxiv·May 14, 2021
- Regulatory landscape of Alzheimer's disease variants in human microglia
Chia-Yi Joy Lee, Ashvin Ravi, … Kristen Brennand·medRxiv·Oct 13, 2025